BioVeris has been felled by a family feud.
Celera Genomics isn't going to start testing its new drug this year after all.
MedImmune's spray flu vaccine was a flop.
Forecasters Look For Hints of Election Results (The Washington Post, Jul 26, 2004)
Penny-Stock Lawyer Nears Day of Reckoning (The Washington Post, Jul 19, 2004)
Playing It Safe In a Sluggish Market (The Washington Post, Jul 12, 2004)
Big Improvements Were Scattered in Quiet 2nd Quarter (The Washington Post, Jul 5, 2004)
Blackboard Insiders Hold Keys to Stock Performance (The Washington Post, Jun 28, 2004)
More Washington Investing Columns
Human Genome Sciences still hasn't delivered on the potential that made it a $100 stock -- four years ago.
Summer is always bad for biotechnology stocks. This summer is particularly nasty.
"For a sector that typically runs hot and cold, biotechs, right now, are downright frosty," writes Adam Feuerstein of TheStreet.com, an online biotech commentator.
Many of the local biotechs are suffering from self-inflicted ailments, but even the others are struggling in the stock market.
Martek Biosciences regularly tops lists of top-rated stocks -- it's one of only 11 stocks in the Russell 2000 index to get straight "buy" ratings -- but investors aren't buying. In the past three months, Martek stock has fallen from $70 a share to $46.
Only United Therapeutics, which is expected to announce solid second-quarter results tomorrow, has held up against the summer selloff. Even with the success of its pulmonary hypertension drug, United Therapeutics' stock is down about a dollar since January.
To biotech analysts, the summer slump means this is a good time to buy. Biotech stocks are always cyclical, they say, so the time to invest is during the down cycle.